Related Experiment Video

Updated: Apr 15, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K

Paediatric pharmacokinetics: key considerations

Hannah Katharine Batchelor, John Francis Marriott

    British Journal of Clinical Pharmacology
    |April 10, 2015
    PubMed

    Insights

    Understanding paediatric drug pharmacokinetics is crucial. This review covers key considerations for designing clinical trials in children, addressing challenges like blood sampling and physiological differences.

    Area of Science:

    • Pharmacology
    • Paediatric Medicine
    • Clinical Trial Design

    Background:

    • Drug pharmacokinetics are influenced by anatomical and physiological factors.
    • Paediatric populations exhibit physiological differences from adults, affecting drug concentrations.
    • Awareness of these changes is vital for healthcare professionals managing paediatric drug dosages.

    Purpose of the Study:

    • To review key considerations in designing and developing paediatric pharmacokinetic clinical trials.
    • To highlight challenges and potential solutions in paediatric drug research.

    Main Methods:

    • Literature review focusing on paediatric pharmacokinetic trials.
    • Discussion of anatomical and physiological factors impacting drug disposition in children.
    • Exploration of alternative blood sampling techniques and population-based modeling.

    Main Results:

    • Paediatric physiology significantly alters drug pharmacokinetics compared to adults.
    • Blood sample volume limitations and pain perception complicate paediatric trials.
    • Alternative sampling methods and population models can mitigate trial challenges.

    Conclusions:

    • Effective paediatric pharmacokinetic trials require careful consideration of age-specific physiology.
    • Minimally invasive techniques and robust modeling are essential for ethical and efficient paediatric drug research.

    More Related Videos

    Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine06:09

    Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine

    Published on: January 12, 2024

    1.1K
    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

    Published on: December 3, 2020

    8.9K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    505
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    391
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    838
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    360
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    886
    Dosage Regimens: Partial Pharmacokinetic Parameters01:01

    Dosage Regimens: Partial Pharmacokinetic Parameters

    It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
    350